Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline among companies warned by EU

GlaxoSmithKline among companies warned by EU

1st December 2008

GlaxoSmithKline (GSK) has been accused of delaying and impeding the entry of generic drugs to the market by the European commissioner for competition.

Neelie Kroes’ comments follow a ten-month investigation into the company and other organisations, which alleged they had collectively cost 17 member states three billion euros (2.5 billion pounds) between 2000 and 2007.

The report said pharmaceutical companies adopted various practices to slow the progress of generic drugs to market, including the filing of large numbers of patents and litigation cases and the arranging of settlements with generic manufacturers.

As a result, Ms Kroes warned the businesses may now have proceedings launched against them.

She said: “It is still early days, but the commission will not hesitate to open anti-trust cases against companies where there are indications that the anti-trust rules may have been breached.”

In other news, GSK has said it has received approval by the US Food and Drug Administration (FDA) for its Promacta (eltrombopag) product.

The item is used as an oral treatment for patients with chronic immune (idiopathic) thrombocytopenic purpura.

GSK makes almost four billion packs of medicines and healthcare products every year and its brands include Lucozade, Ribena, Aquafresh, Zovirax, Horlicks, Sensodyne and Panadol.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.